Bayer and Aignostics to collaborate on next generation precision oncology

"Together with Bayer, we’re excited to transform AI’s immense potential into a reality for healthcare"

18-Mar-2024 - Bayer and Aignostics GmbH announced a strategic collaboration on several artificial intelligence (AI)-powered approaches with applications in precision oncology drug research and development. Aignostics is a spin-off from one of the world’s leading hospitals, Charité-Universitätsmedizin Berlin, ...

NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures

Advance Novel Immuno-Oncology Programs

12-Jan-2023 - NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. The ...

Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics

Acquisition strengthens Bayer’s drug discovery capabilities with cutting-edge chemoproteomics platform

09-Aug-2021 - Bayer AG announced the acquisition of Vividion Therapeutics, Inc. (Vividion), a US-headquartered biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics. Vividion’s platform is able to produce a variety ...

Bayer Expands Collaboration with Broad Institute of MIT and Harvard

01-Apr-2015 - Bayer HealthCare (Bayer) has expanded its collaboration with the Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard University to include cardiovascular genomics and drug discovery. The goal of this new part of the alliance is to leverage insights from human genetics to ...

Bayer to divest Interventional device business for $415 million

19-May-2014 - Bayer HealthCare has entered into a definitive agreement to sell its Interventional device business to Boston Scientific. The total consideration for the transaction, including fees for transitional services, is $415 million (about EUR 300 million). The sale will include the AngioJet™ ...

KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification

19-Oct-2009 - KINAXO Biotechnologies GmbH and Bayer Vital GmbH announced that they will enter into collaboration. KINAXO will apply its quantitative phosphoproteomics technology PhosphoScout® for the identification of novel biomarkers in a clinical trial conducted by Bayer Vital. Accompanying a clinical trial ...

Nexavar in Combination with Chemotherapy Shown To Extend Progression-Free Survival in Patients with Advanced Breast Cancer

Statistically Significant Results Reported from a Phase II Study Combining Two Oral Cancer Therapies

24-Jul-2009 - Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. today announced that their first cooperative group-sponsored randomized Phase II trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival. The study evaluated Nexavar® (sorafenib) tablets in combination ...

Genzyme Completes Transaction with Bayer HealthCare

Assumes Primary Responsibility for Alemtuzumab in Multiple Sclerosis

04-Jun-2009 - Genzyme Corp. announced that it has completed the transaction with Bayer HealthCare to acquire the worldwide rights to Campath®/MabCampath® (alemtuzumab), giving Genzyme primary responsibility for the development and commercialization of this multiple sclerosis (MS) therapeutic candidate. Genzyme ...

Genzyme and Bayer HealthCare Enter New Strategic Agreement

Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis

02-Apr-2009 - Genzyme Corporation announced that it has entered into an agreement to acquire the worldwide rights to Campath® (alemtuzumab) from Bayer HealthCare, giving Genzyme primary responsibility for the development and commercialization of this potential break-though treatment for multiple sclerosis ...

Bayer Strengthens Research and Development

Pharmaceutical pipeline is well filled, with 50 projects currently in phases I to III of clinical testing

16-Dec-2008 - The Bayer Group is to further expand its research and development activities despite the current financial and economic crisis. “The task now is to set the right course. Only through innovation can our company generate the growth that is essential to safeguard its sustained success,” said Werner ...